REG - Malin Corp PLC - Litigation Update

MalinAnnouncement

20/06/2022 12:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220620:nRST4841Pa&default-theme=true

RNS Number : 4841P  Malin Corporation PLC  20 June 2022

Malin Corporation plc

 

Defamation proceedings issued on behalf of Kelly Martin & Sean Murphy

 

Dublin-Ireland, 20 June 2022: Malin Corporation plc (Euronext Growth
Dublin:MLC) ("Malin", the "Company"), a company investing in highly innovative
life sciences companies, today confirms it is aware that defamation
proceedings were issued on behalf of Kelly Martin and Sean Murphy against
Malin, Malin's chair, Liam Daniel, and Malin's CEO, Darragh Lyons.

 

The Company, Mr Daniel and Mr Lyons dispute the basis for the claim and
confirm that the proceedings will be fully defended.

 

ENDS

 

About Malin Corporation plc

Malin (Euronext Growth Dublin:MLC) invests in and supports highly innovative
life sciences companies developing exceptional science and technology to
deliver transformative outcomes for patients and create significant value for
shareholders.

Our purpose is to create shareholder value through the application of
long-term capital and strategic support to its investee companies to enable
them to reach their value potential. Malin is headquartered and domiciled in
Ireland and listed on the Euronext Growth Dublin. For more information
visit www.malinplc.com

For further information contact:

 

Malin

Fiona Dunlevy, Company Secretary

Tel: +353 (0)1 901 5700

investorrelations@malinplc.com

 

Davy Corporate Finance (Euronext Growth Adviser & Joint Broker)

Brian Garrahy / Daragh O'Reilly

Tel: +353 1 679 6363

 

Liberum (Joint Broker)

Phil Walker / Ben Cryer

Tel: +44 (0) 20 3100 2000

 

Powerscourt (Media enquiries)

Eavan Gannon

Tel: +353 87 236 5973

malin@powerscourt-group.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCURSRRUAUNUAR